Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DVA
stocks logo

DVA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.51B
+6.42%
3.192
+42.51%
3.35B
+3.94%
2.459
+22.93%
3.45B
+2.09%
3.331
+12.9%
Estimates Revision
The market is revising Upward the revenue expectations for DaVita Inc. (DVA) for FY2025, with the revenue forecasts being adjusted by 0.72% over the past three months. During the same period, the stock price has changed by -13.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.12%
In Past 3 Month
Stock Price
Go Down
down Image
-13.48%
In Past 3 Month
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 139.00 USD with a low forecast of 133.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 139.00 USD with a low forecast of 133.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
1 Sell
Hold
Current: 117.280
sliders
Low
133.00
Averages
139.00
High
143.00
Current: 117.280
sliders
Low
133.00
Averages
139.00
High
143.00
TD Cowen
Gary Taylor
Hold
downgrade
$154 -> $133
2025-11-03
Reason
TD Cowen
Gary Taylor
Price Target
$154 -> $133
2025-11-03
downgrade
Hold
Reason
TD Cowen analyst Gary Taylor lowered the firm's price target on DaVita to $133 from $154 and keeps a Hold rating on the shares. The firm noted they missed 3Q25 EBIT by -10%, but they attribute a portion to Street mis-modeling while the recent pullback has Dthe shares shares looking more appealing, but a continued tepid volume outlook offsets upside.
Barclays
Equal Weight
maintain
$149 -> $143
2025-10-30
Reason
Barclays
Price Target
$149 -> $143
2025-10-30
maintain
Equal Weight
Reason
Barclays lowered the firm's price target on DaVita to $143 from $149 and keeps an Equal Weight rating on the shares post the Q3 report. The firm says an "unusual quarterly progression" drove a large disparity between DaVita's internal plan and Street estimates, resulting in a big headline miss but guidance reiteration.
Truist
David MacDonald
Hold
downgrade
$148 -> $140
2025-10-14
Reason
Truist
David MacDonald
Price Target
$148 -> $140
2025-10-14
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on DaVita to $140 from $148 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.
BofA
analyst
Underperform
downgrade
$145 -> $140
2025-09-10
Reason
BofA
analyst
Price Target
$145 -> $140
2025-09-10
downgrade
Underperform
Reason
BofA lowered the firm's price target on DaVita to $140 from $145 and keeps an Underperform rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.
Truist
David MacDonald
Hold
downgrade
$164 -> $148
2025-08-08
Reason
Truist
David MacDonald
Price Target
$164 -> $148
2025-08-08
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on DaVita to $148 from $164 and keeps a Hold rating on the shares. The firm is adjusting its estimates to reflect the company's Q2 results, raising its FY25 EPS view by 14c to $10.88 but cutting its price target to reflect a lower assumed multiple, the analyst tells investors in a research note.
Barclays
Equal Weight
downgrade
$169 -> $160
2025-08-07
Reason
Barclays
Price Target
$169 -> $160
2025-08-07
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on DaVita to $160 from $169 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says DaVita's treatment growth and revenue per treatment were revised down as cyberattack disruptions drove higher missed treatment rates and revenue cycle challenges.
See All Ratings

Valuation Metrics

The current forward P/E ratio for DaVita Inc (DVA.N) is 9.60, compared to its 5-year average forward P/E of 12.90. For a more detailed relative valuation and DCF analysis to assess DaVita Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
12.90
Current PE
9.60
Overvalued PE
14.80
Undervalued PE
11.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.44
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.27
Undervalued EV/EBITDA
8.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.85
Current PS
0.00
Overvalued PS
1.02
Undervalued PS
0.68
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 6939.07% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DVA News & Events

Events Timeline

(ET)
2025-11-14
16:19:49
Berkshire Hathaway increases investment in Alphabet while reducing its holdings in Apple.
select
2025-10-29 (ET)
2025-10-29
16:08:33
DaVita announces Q3 adjusted EPS of $2.51, falling short of consensus estimate of $3.17
select
2025-08-20 (ET)
2025-08-20
16:16:47
DaVita Boosts Current Share Buyback Program by $2 Billion
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-25Barron's
Alphabet Shares Boost Berkshire's Portfolio with a 40% Increase So Far.
  • Berkshire Hathaway's Investment Timing: Berkshire Hathaway was delayed in purchasing shares of Alphabet.
  • Positive Market Performance: Despite the late entry, the investment is proving beneficial due to a significant rally in Alphabet's stock.
[object Object]
Preview
5.0
11-15Benzinga
Warren Buffett Starts Investment in Alphabet and Reduces Apple Holdings in Q3 — A Look at Berkshire's Actions

  • New Positions: In the third quarter, Berkshire Hathaway acquired a new position in Alphabet Inc Class A, totaling 17,846,142 shares, making it a top-10 holding for the company.

  • Exited Positions: Berkshire Hathaway exited its investment in D.R. Horton Inc, a stock it had purchased in the previous quarter.

  • Changes to Positions: The company increased its stakes in several stocks, including Chubb Limited (+16%) and Domino's Pizza (+13%), while reducing its holdings in Apple Inc (-15%) and VeriSign Inc (-32%).

  • Top Holdings: Berkshire's largest holdings remain Apple (23%), American Express (19%), and Bank of America (11%), with Alphabet Inc now at 1.6% of the portfolio.

[object Object]
Preview
1.0
11-15Newsfilter
DaVita Inc. to Join Wolfe Research for Fireside Chat

  • Fireside Chat Announcement: DaVita Inc.'s CFO, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on November 17, 2025, at 11:20 am EST, with a live webcast available for viewing.

  • Company Overview: DaVita Inc. is a leading healthcare provider specializing in kidney care, serving approximately 293,200 patients across 3,247 outpatient dialysis centers globally, with a focus on improving patient quality of life and clinical outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is DaVita Inc (DVA) stock price today?

The current price of DVA is 117.28 USD — it has decreased -0.82 % in the last trading day.

arrow icon

What is DaVita Inc (DVA)'s business?

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.

arrow icon

What is the price predicton of DVA Stock?

Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 139.00 USD with a low forecast of 133.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is DaVita Inc (DVA)'s revenue for the last quarter?

DaVita Inc revenue for the last quarter amounts to 3.42B USD, increased 4.80 % YoY.

arrow icon

What is DaVita Inc (DVA)'s earnings per share (EPS) for the last quarter?

DaVita Inc. EPS for the last quarter amounts to 2.04 USD, decreased -18.40 % YoY.

arrow icon

What changes have occurred in the market's expectations for DaVita Inc (DVA)'s fundamentals?

The market is revising Upward the revenue expectations for DaVita Inc. (DVA) for FY2025, with the revenue forecasts being adjusted by 0.72% over the past three months. During the same period, the stock price has changed by -13.48%.
arrow icon

How many employees does DaVita Inc (DVA). have?

DaVita Inc (DVA) has 76000 emplpoyees as of December 05 2025.

arrow icon

What is DaVita Inc (DVA) market cap?

Today DVA has the market capitalization of 8.28B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free